Thermo Fisher Scientific Inc

Latest Thermo Fisher Scientific Inc News and Updates

  • Raw materials in a steel factory
    Company & Industry Overviews

    Materials Sector Stocks Weigh Market Down, Might Be Time to Buy

    The materials sector has been among the worst hit in the market. Is now the time to invest for long-term growth?
    By Rachel Curry
  • uploads///Xamarin
    Miscellaneous

    Microsoft Infiltrates the Mobile App Space: The Xamarin Acquisition

    On February 24, Microsoft announced that it will acquire Xamarin, a mobile app platform provider. Financial details of the deal were not disclosed.

    By Anne Shields
  • uploads///AXDX analysts Reco
    Company & Industry Overviews

    What Analysts Recommend for Accelerate Diagnostics and Peers

    Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.

    By Kenneth Smith
  • What Are Leon Cooperman’s Top Holdings?
    Financials

    What Are Leon Cooperman’s Top Holdings?

    In Q3, billionaire investor Leon Cooperman’s top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.

    By Rabindra Samanta
  • uploads///valuation
    Company & Industry Overviews

    How Hologic’s Valuation Stacks Up with Peers

    The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

    By Sarah Collins
  • uploads///piron guillaume  unsplash
    Earnings Report

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

    By Sarah Collins
  • uploads///CASH FLOW
    Company & Industry Overviews

    How Tax Reform Affected Medtronic’s 3Q18 Performance

    Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]

    By Sarah Collins
  • uploads///hospital _
    Company & Industry Overviews

    A Look at Hologic Stock’s Recent Performance

    Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.

    By Sarah Collins
  • uploads///core strategies
    Company & Industry Overviews

    How Are Stryker’s Core Strategies Working Toward Its Growth?

    Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    BD’s Stock Price Performance after Recent 52-Week High

    On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Has Boston Scientific Stock Performed Recently?

    Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • Healthcare

    Why is leverage a double-edged sword for companies like Apple?

    Corporate bond issuance in the U.S. reached $1.4 trillion in 2013, according to the Securities Industry and Financial Markets Association (SIFMA), a new record.

    By Phalguni Soni
  • uploads///microbiology _
    Company & Industry Overviews

    Illumina Stock Continues Its Bull Run

    Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.

    By Sarah Collins
  • uploads///core strategies
    Company & Industry Overviews

    How Stryker’s Margins Are Driven by Its CTG Program

    Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.

    By Sarah Collins
  • uploads///TMO
    Company & Industry Overviews

    Thermo Fisher Scientific’s Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Analysts Remain Bullish on Illumina Stock

    In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Gross Margin Trend

    Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Geographical Performance

    For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

    By Kenneth Smith
  • uploads///lab _
    Earnings Report

    Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings

    Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Thermo Fisher’s Third-Quarter Revenue Estimates

    The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.

    By Mike Benson
  • uploads///analysis _
    Earnings Report

    What to Expect from Thermo Fisher’s Third-Quarter Earnings

    Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.

    By Mike Benson
  • uploads///earnings estimates
    Earnings Report

    Edwards Lifesciences’ Q3 2018 Earnings Estimates

    Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.

    By Sarah Collins
  • uploads///sales estimates
    Earnings Report

    What to Expect of Edwards Lifesciences’ Q3 2018 Sales

    Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.

    By Sarah Collins
  • uploads///RMD ana reco
    Company & Industry Overviews

    What ResMed’s Valuation Trend Indicates

    The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.

    By Kenneth Smith
  • uploads///A ana reco
    Company & Industry Overviews

    What’s the Upside Potential for Agilent Technologies Stock?

    In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.

    By Kenneth Smith
  • uploads///WAT ana reco
    Company & Industry Overviews

    What Waters Corporation’s Valuation Trend Indicates

    In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”

    By Kenneth Smith
  • uploads///valuation
    Company & Industry Overviews

    Is Abbott Laboratories Trading at a High Valuation in September?

    Abbott stock has been gaining momentum recently, and its valuation has improved.

    By Sarah Collins
  • uploads///laboratory _
    Company & Industry Overviews

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.

    By Kenneth Smith
  • uploads///TMO drivres
    Company & Industry Overviews

    What’s Driving the Growth in Thermo Fisher Scientific’s Segments?

    Thermo Fisher Scientific (TMO) operates in four business segments.

    By Kenneth Smith
  • uploads///hologic recommendations
    Company & Industry Overviews

    Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock

    As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

    By Mike Benson
  • uploads///chemist _
    Company & Industry Overviews

    How Thermo Fisher Scientific’s Valuation Looks in September

    Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.

    By Mike Benson
  • uploads///conclusion of the contract __
    Company & Industry Overviews

    How BD Stock Has Performed in the Last Year

    On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results

    Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.

    By Sarah Collins
  • uploads///AXDX RD Expenses
    Company & Industry Overviews

    What Are Accelerate Diagnostics’ Key Strengths?

    In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.

    By Kenneth Smith
  • uploads///AXDX revenue growth
    Company & Industry Overviews

    Does Accelerate Diagnostics’ Financial Performance Bode Well?

    The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.

    By Kenneth Smith
  • uploads///q guidance
    Company & Industry Overviews

    Baxter International Expected to Post Strong 4Q17 Results

    Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    A Look at Thermo Fisher Scientific’s Recent Stock Price Performance

    TMO stock reported its 52-week high of $201.20 on October 26, 2017, when the company released its 3Q17 earnings results.

    By Sarah Collins
  • uploads///product segments
    Company & Industry Overviews

    TMO’s Acquisition from EPTEK Technology Could Boost Its China Opportunity

    On December 4, 2017, Thermo Fisher Scientific (TMO) completed the acquisition of some assets from EPTEK Technology and related entities that have offices in mainland China and Taiwan.

    By Sarah Collins
  • uploads///digital science capabilities
    Company & Industry Overviews

    Thermo Fisher Scientific’s Deepening Ties with Sema4

    Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.

    By Sarah Collins
  • uploads///GENETIC ANALYSIS GROWTH STRATEGY
    Company & Industry Overviews

    TMO’s Launch of New Research Assay for Cancer

    On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.

    By Sarah Collins
  • uploads///quantstudio
    Company & Industry Overviews

    Thermo Fisher Expands Its Partnership with Genome Diagnostics

    In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.

    By Sarah Collins
  • uploads///operatingmargin
    Company & Industry Overviews

    What’s Driving BD’s Operating Margin Expansion

    Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]

    By Sarah Collins
  • uploads///ALR ABT acquisition
    Company & Industry Overviews

    Understanding Abbott’s Alere Acquisition: What We Can Expect

    On October 3, 2017, Abbott announced the completion of its acquisition of Alere, which has had troubles since the initial announcement in February 2016.

    By Sarah Collins
  • uploads///guidance
    Company & Industry Overviews

    Baxter International’s Latest Guidance for Fiscal 2017

    Baxter International’s sales growth guidance for fiscal 2017 is expected to be ~4% on a reported basis.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Understanding BD’s Recent Stock Performance

    BD has a 50-day moving average of $197.25, while its 200-day moving average is $192.35.

    By Sarah Collins
  • uploads///life sciences strategy
    Company & Industry Overviews

    Latest Product Launch Expands BD’s Genomics Portfolio

    Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.

    By Sarah Collins
  • uploads///EPS ESTIMATES
    Company & Industry Overviews

    Inside Baxter International’s Stock Price Performance

    On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Taking a Look at Stryker’s Recent Stock Price Performance

    On August 31, Stryker (SYK) closed trading at a closing price of $139.3. It has a 50-day moving average of $144.7 and a 200-day moving average of $137.5.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Which Way Are Zimmer Biomet’s Analysts Leaning after 2Q17?

    Of the 29 brokerage firms tracking Zimmer Biomet, 18 (62%) analysts gave ZBH stock a “buy” rating, while nine (~31%) provided a “hold” rating.

    By Sarah Collins
  • uploads///EMERGING MARKET PERFORMANCE
    Company & Industry Overviews

    How Is Becton Dickinson Progressing with Emerging Market Growth?

    Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.

    By Sarah Collins
  • uploads///PROJECTIONS
    Earnings Report

    What Investors Can Expect from Medtronic’s Fiscal 1Q18 Results

    In fiscal 4Q17, Medtronic’s revenue came in at $7.9 billion, representing YoY (year-over-year) growth of ~5%.

    By Sarah Collins
  • uploads///PERFORMANCE
    Earnings Report

    Key Highlights of Varian Medical Systems’ Fiscal 2Q17 Earnings

    On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.

    By Sarah Collins
  • uploads///stock price
    Earnings Report

    How Thermo Fisher Scientific’s Stock Has Performed

    Thermo Fisher Scientific (TMO) closed trading at $175.3 on July 27, 2017.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Stryker Exceeded Analysts’ Sales Estimates in 2Q17

    On July 27, 2017, Stryker (SYK) released its 2Q17 earnings. The company reported strong earnings and exceeded analysts’ expectations.

    By Sarah Collins
  • uploads///life sciences group
    Company & Industry Overviews

    Thermo Fisher Scientific Accelerates Its Semiconductor Sequencing

    On June 29, 2017, Thermo Fisher Scientific (TMO) announced the addition of three new products to its semiconductor failure analysis workflows portfolio.

    By Sarah Collins
  • uploads///RECOMMENDATIONS
    Company & Industry Overviews

    Most Analysts Recommend ‘Buys’ on Thermo Fisher Scientific

    In a recent Reuters survey of 17 brokerage companies, Thermo Fisher Scientific received “buy” ratings from ~88% of analysts, while ~12% gave it “hold” ratings.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Varian Medical Systems: Analyzing Its Stock Performance

    Varian Medical Systems (VAR) was trading at $102.7 on June 29, 2017. It has a 50-day moving average of $100.4 and a 200-day moving average of $88.8.

    By Sarah Collins
  • uploads///growth drivers
    Company & Industry Overviews

    FDA Warning Letter to Zimmer Biomet Resolved, Boosts Confidence

    On June 13, 2017, Zimmer Biomet (ZBH) announced that the FDA warning letter issued in June 2015 relating to its Zhejiang manufacturing facility in China has been closed.

    By Sarah Collins
  • uploads///stock
    Company & Industry Overviews

    Behind Thermo Fisher’s Recent Stock Performance

    TMO stock was trading at $173.2 on May 30, 2017. The stock had a 50-day moving average of $165.9 and a 200-day moving average of $153.8 that day.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Zimmer Biomet Stock Has Performed Recently

    Zimmer Biomet Holdings (ZBH) was trading at $118.40 on May 30, 2017. It has a 50-day moving average of $119.70 and a 200-day moving average of $114.20.

    By Sarah Collins
  • uploads///CAPITAL DEPLOYMENT
    Company & Industry Overviews

    Understanding Thermo Fisher’s Capital Deployment Strategy

    Thermo Fisher Scientific expects to deploy 60%–75% of its capital toward M&As (mergers and acquisitions).

    By Sarah Collins
  • uploads///innovation
    Company & Industry Overviews

    Understanding Thermo Fisher’s Growth Strategy

    Thermo Fisher Scientific (TMO) has always focused on innovation as a key growth strategy.

    By Sarah Collins
  • uploads///asia pacific
    Company & Industry Overviews

    How Long Can Thermo Fisher Scientific’s Asia-Pacific Growth Momentum Last?

    Thermo Fisher Scientific (TMO) has a presence around the globe, but around 80% of its revenues are generated from developed markets.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Abbott Is Expected to Report a Modest Rise in Net Profit Margins

    Abbott Laboratories (ABT) has projected its 2017 gross margin to be ~60%, higher than the 57.3% it reported in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Abbott Laboratories Still Dominates the Medical Device Segment

    In 2017, Abbott Laboratories (ABT) plans to focus on the integration of St. Jude Medical’s medical device business, realizing deal synergies, and achieving financial targets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Bio-Rad Laboratories Expects from Life Science

    In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017

    On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bio-Rad Laboratories on the Street: Analysts’ Recommendations in May

    In 1Q17, Bio-Rad Laboratories (BIO) reported revenues of ~$500.1 million, which represented a YoY (year-over-year) rise of around 6.1%.

    By Margaret Patrick
  • uploads///CHART
    Macroeconomic Analysis

    Trump Trade Fades amid Political Debacle: What’s the Impact?

    As part of Obamacare, a medical device tax of 2.3% has been implemented on medical device companies in the United States.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    What Analysts Recommend for Stryker after 1Q17 Results

    The consensus 12-month target price for Stryker is $141, a ~3.5% return potential.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    How ZBH Stock Has Performed Recently

    Zimmer Biomet Holdings (ZBH) was trading at $123.3 as of April 24, 2017.

    By Sarah Collins
  • uploads///REVENUE ESTIMATES
    Earnings Report

    Why Zimmer Biomet Could See Revenue Growth in 1Q17

    Wall Street analysts expect Zimmer Biomet’s 1Q17 revenue to be about $1.96 billion, a ~3% increase on a YoY (year-over-year) basis.

    By Sarah Collins
  • uploads///MED_DEVICE
    Earnings Report

    Behind JNJ’s Medical Devices Growth Trajectory

    In 1Q17, Johnson & Johnson’s (JNJ) Medical Device segment revenues came in at ~$6.3 billion, as compared to $6.1 billion in 1Q16.

    By Sarah Collins
  • uploads///LIFESCIENCES PIPELINE
    Company & Industry Overviews

    BD Lifesciences’s Product Pipeline Could Boost Its Fiscal 2017 Growth

    Becton, Dickinson and Company (BDX) recently launched BD Barricor and BD Ultra Touch Push Button under its Pre-Analytical Systems division.

    By Sarah Collins
  • uploads///GROWTH
    Company & Industry Overviews

    Becton Dickinson’s Long-Term Growth Profile and Expectations

    After executing its growth strategies during the last five years, Becton, Dickinson and Company (BDX) has achieved its targeted growth rates of 5% top-line organic growth and 10% bottom-line growth.

    By Sarah Collins
  • uploads///fei
    Company & Industry Overviews

    How Is Thermo Fisher Scientific’s FEI Integration Process Going?

    Thermo Fisher Scientific (TMO) completed the acquisition of FEI Company on September 19, 2016.

    By Sarah Collins
  • uploads///ctg
    Company & Industry Overviews

    Exploring the Nuances of Stryker’s Cost Transformation for Growth

    Cost transformation growth is one of Stryker’s key strategies for driving growth. The company has come a long way from its decentralized structure prior to 2010.

    By Sarah Collins
  • uploads///obamacare
    Company & Industry Overviews

    How Will the US Election’s Results Impact Stryker’s Business?

    Stryker (SYK) believes that the election of Donald Trump as the new US president could be good news for the US medical device industry.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Are Analysts’ Latest Recommendations for Stryker?

    In a Reuters survey of 26 brokerage companies on November 18, 2016, about 61.5% of analysts rated it as a “buy,” and 30.8% rated it as a “hold.”

    By Sarah Collins
  • uploads///STOCK
    Earnings Report

    How Did Stryker’s Stock Perform after Its 3Q Earnings Release?

    Stryker (SYK) was trading at $114.30 on October 28, 2016, with a 50-day moving average of $114.70 and a 200-day moving average of $114.60.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    Analyzing Johnson & Johnson’s Recent Stock Performance

    Johnson & Johnson (JNJ) was trading at $114.90 on October 20, 2016, with a 50-day moving average of $118.40 and a 200-day moving average of $117.60.

    By Sarah Collins
  • uploads///emerging markets
    Company & Industry Overviews

    TMO Focused on Strengthening Its Emerging Market Presence

    Thermo Fisher Scientific (TMO) has grown in double digits in China, which is now the company’s second-largest market by geography.

    By Sarah Collins
  • uploads///reveneus
    Company & Industry Overviews

    Thermo Fisher Scientific’s Key Growth Strategy

    Thermo Fisher Scientific reported ~$4.5 billion in revenues in 2Q16, representing YoY (year-over-year) growth of ~6%.

    By Sarah Collins
  • uploads///Portfolio Breakdown of the MFEGX
    Financials

    Noteworthy Portfolio Changes in the MFS Growth Fund

    The MFS Growth Fund Class A’s assets were invested across 87 holdings as of June 2016, and it was managing assets worth $12 billion as of the end of June.

    By David Ashworth
  • uploads///ppi
    Company & Industry Overviews

    Can Thermo Fisher’s PPI Business System Continue to Drive Growth in 2016?

    The PPI system has helped nourish strong top-line growth across Thermo Fisher’s businesses while boosting margins.

    By Sarah Collins
  • uploads///innovation
    Company & Industry Overviews

    How Innovation Is Driving Thermo Fisher Scientific’s Growth

    Thermo Fisher Scientific now has more than 800,000 products in its portfolio and has an extensive product pipeline.

    By Sarah Collins
  • uploads///commercial
    Company & Industry Overviews

    How Are Thermo Fisher’s Commercial Capabilities Driving Its Share Gains?

    Thermo Fisher Scientific is a leading provider of laboratory and analytical products and services. It’s a leader in the majority of its device segments.

    By Sarah Collins
  • uploads///emerging markets
    Company & Industry Overviews

    Inside Thermo Fisher Scientific’s Emerging Markets Strategy

    Thermo Fisher has a presence in more than 50 countries. It generates ~19% of its revenues from emerging markets and the rest from developed markets.

    By Sarah Collins
  • uploads///fin model
    Company & Industry Overviews

    Understanding Thermo Fisher Scientific’s Financial Model

    Thermo Fisher Scientific aims to deliver adjusted EPS in the range of $11.3–$12.2 by 2019. This represents a three-year CAGR of 12%–15%.

    By Sarah Collins
  • uploads///radiotherapy gaps
    Company & Industry Overviews

    Varian Medical Systems’ Growth Potential in Radiation Oncology

    Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.

    By Sarah Collins
  • uploads///analyst recommendations
    Earnings Report

    What Do Analysts Recommend for Medtronic ahead of 4Q16 Results?

    In a Bloomberg survey of 26 brokerage companies on May 26, 2016, about 81% of analysts rated Medtronic as a “buy,” and 19% rated it as a “hold.”

    By Sarah Collins
  • uploads///hospital products
    Earnings Report

    Innovation Drove Baxter’s Hospital Products Sales in 1Q16

    Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$1.5 billion was contributed by the company’s Hospital Products business.

    By Sarah Collins
  • uploads///diagnostics
    Earnings Report

    Strong Revenue for Abbott Point of Care Diagnostics Division

    Abbott Laboratories (ABT) reported $5.2 billion of revenues worldwide in 4Q15. Of that, $1.2 billion was generated through Abbott Point of Care diagnostics.

    By Sarah Collins
  • uploads///nutrition operatinng margin
    Company & Industry Overviews

    Why Abbott Laboratories Is a Leader in Nutritional Products

    Abbott Laboratories’ Nutritional Products segment is the company’s leading segment, growing at a fast pace, with rapidly increasing margins and revenues.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    IHI Large-Caps: Baxter Launches Mobile Health App in India

    In a press release, Baxter International (BAX) announced that it has launched a new mobile app in India called Sisu Janani Seva. It’s also known as mHealth.

    By Peter Neil
  • uploads///strategic initiatives
    Company & Industry Overviews

    Behind Becton Dickinson’s Strategic Restructuring and Business Consolidation

    To better position itself amid the changing medical device environment, Becton Dickinson has come to focus on restructuring and business model evolution.

    By Sarah Collins
  • uploads///revenues
    Company & Industry Overviews

    How a Strong Product Portfolio Drives Thermo Fisher’s Valuations

    Thermo Fisher Scientific (TMO) registered sales of $4.7 billion, representing year-over-year growth of 4% in 4Q15 and fiscal 2015 sales of ~$17 billion.

    By Sarah Collins
  • uploads///geographic segmentation
    Company & Industry Overviews

    The Geographic Strategy of Thermo Fisher Scientific

    Thermo Fisher Scientific is a global company, but the majority of its revenues are generated from the developed markets. The US is its largest market, generating ~48% of the company’s total revenues.

    By Sarah Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.